{"id":3809,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/carboplatin-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"carboplatin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/carboplatin-txt\/","title":{"rendered":"Carboplatin.txt"},"content":{"rendered":"

Carboplatin<\/h1>\n

CLINICAL USE <\/H3>
\nAntineoplastic agent:<\/p>\n
  • Ovarian carcinoma of epithelial origin\n
  • Small cell carcinoma of the lung

    DOSE IN NORMAL RENAL FUNCTION <\/H3>Dose = Target AUC \u00d7 [GFR (mL\/min) + 25]where AUC is commonly 5 or 6 depending on protocol used (Calvert equation)

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :371.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :29\u201389<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 32\u201370<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.23\u20130.28<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1.5\u20136\/ Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Aminoglycosides: increased risk of nephrotoxicity and possibly ototoxicity with aminoglycosides, capreomycin, polymyxins or vancomycin\n
  • Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>IV

    Rate of Administration <\/H4>

    IV infusion <\/H4> over 15\u201360 minutes

    Comments<\/H4>\n
  • Therapy should not be repeated until 4 weeks after the previous carboplatin course\n
  • May be diluted with glucose 5%, or sodium chloride 0.9% to concentrations as low as 0.5 mg\/mL

    OTHER INFORMATION <\/H4>\n
  • Patients with abnormal kidney function or receiving concomitant therapy with nephrotoxic drugs are likely to experience more severe and prolonged myelotoxicity\n
  • Blood counts and renal function should be monitored closely\n
  • Some units still use a dose in normal renal function of 400 mg\/m2. In this instance, the dose should be reduced to 50% of normal for a GFR of 10 to 20 mL\/min, and to 25% of normal for a GFR <10 mL\/min\n
  • There is little, if any, true metabolism of carboplatin. Excretion is primarily by glomerular filtration in the urine, with most of the drug excreted in the first 6 hours. Approximately 32% of the dose is excreted unchanged.\n
  • Platinum from carboplatin slowly becomes protein bound, and is subsequently excreted with a terminal half-life of 5 days or more.
    \n","protected":false},"excerpt":{"rendered":"

    Carboplatin CLINICAL USE Antineoplastic agent: Ovarian carcinoma of epithelial origin<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3809","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3809"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3809\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}